Economic Consequences of the Wolf Comeback in the Western United States

Gray wolves were eradicated from most of the United States in the 1940’s but have made a comeback in parts of their historic range over the last two decades. First reintroduced into the Greater Yellowstone Ecosystem and central Idaho in the mid-1990’s, wolves have subsequently dispersed into at least 7 western states. Coloradoans became the latest state to take interest in bolstering wolf populations, as residents passed a ballot initiative in November 2020 to reintroduce a self-sustaining population of gray wolves by the end of 2023. Conflicts between people in rural areas that might incur costs (such as livestock loss) and people in urban areas geographically removed from direct contact with wolves suggest that the distribution of benefits may not align uniformly with the distribution of costs. Given that Colorado will imminently make many policy decisions that have an impact on costs and benefits, we review available literature to better understand the magnitude of gainers and losers from wolf reintroduction in western states. Although no single study has included all possible economic values, the magnitude of impacts can be inferred by assembling a broad range of estimates for different types of values into a single space. Our review of existing valuation literature from western states indicates that the magnitude of economic benefits of wolves is many times higher than what it costs to manage wolves and to reduce or compensate for losses to livestock producers and others

Willingness to pay for reintroducing wolves in a divided voting base

Wolves will soon be reintroduced in Colorado based on a statewide ballot initiative that narrowly passed in November 2020. Using an economic choice experiment, we estimate the benefits that wolf introduction might bring to Colorado. We calculated willingness to pay (WTP) for a sustainable wolf population by considering six program attributes: 1) state wolf population, 2) compensation for livestock-related losses, 3) cost-sharing for conflict reduction, 4) number of livestock killed statewide, 5) lethal government control of wolves, and 6) wolf hunting. Respondents who reported they voted yes on the ballot initiative had a positive WTP for a population of 200 wolves, referred to as the minimum sustainable population in the survey, but WTP diminished for larger populations. Preferences for a population of 200 wolves amounts to an annual WTP of approximately $31.1 million when extrapolating to all yes-voting households statewide. In contrast, respondents who reported they voted no would have to be paid to accept wolf populations. We also found statistically significant preferences for other attributes of the management program, such as cost sharing for conflict reduction measures to livestock producers or compensating livestock losses. When these attributes were included, the willingness to pay increased to$115 million statewide among yes-voting households. We estimated a $57.5 to$1 benefit-cost ratio for a sustainable wolf population. However, benefits and costs are not evenly distributed across urban and rural residents, which suggests that mechanisms to transfer resources from those willing to pay to those that incur costs would be needed to balance that distribution

Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia

Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. We performed systematic database search and identified highly specific MED12 mutations in CLL patients. To study this further, we collected three independent sample series comprising over 700 CLL samples and screened MED12 exons 1 and 2 by direct sequencing. Mutations were identified at significant frequency in all three series with a combined mutation frequency of 5.2% (37/709). Positive mutation status was found to be associated with unmutated IGHV and ZAP70 expression, which are well-known poor prognosis markers in CLL. Our results recognize CLL as the first extrauterine cancer type where 5'terminus of MED12 is mutated at significant frequency. Functional analyses have shown that these mutations lead to dissociation of Cyclin C-CDK8/19 from the core Mediator and to the loss of Mediator-associated CDK kinase activity. Additional studies on the role of MED12 mutation status as a putative prognostic factor as well as mutations' exact tumorigenic mechanism in CLL are warranted.Peer reviewe

Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia.

Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. We performed systematic database search and identified highly specific MED12 mutations in CLL patients. To study this further, we collected three independent sample series comprising over 700 CLL samples and screened MED12 exons 1 and 2 by direct sequencing. Mutations were identified at significant frequency in all three series with a combined mutation frequency of 5.2% (37/709). Positive mutation status was found to be associated with unmutated IGHV and ZAP70 expression, which are well-known poor prognosis markers in CLL. Our results recognize CLL as the first extrauterine cancer type where 5'terminus of MED12 is mutated at significant frequency. Functional analyses have shown that these mutations lead to dissociation of Cyclin C-CDK8/19 from the core Mediator and to the loss of Mediator-associated CDK kinase activity. Additional studies on the role of MED12 mutation status as a putative prognostic factor as well as mutations' exact tumorigenic mechanism in CLL are warranted

Kinetic constraints on the In-situ remediation of soils contaminated with organic chemicals.

Cleanup of contaminated soils to comply with soil quality limits currently receives much interest.In-situ remediation of contaminated soils relies on the ability of the techniques employed to enhance the rate of release of contaminants from the soil-sorbed and nonaqueous phase liquid (NAPL) phases into the aqueous or gaseous phases from which they can be more readily removed and treated. Contaminant concentrations in these “environmentally mobile” forms usually decline over time so that the economic efficiency and the overall success of remediation technologies are subject to the “law of diminishing returns”. In this paper we consider the “state of the art” in our understanding of NAPL dissolution and transport, desorption of soilsorbed contaminants and fluid flow in porous media. The extent to which these processes may constrain the success of bioremediation, pump-and-treat remediation and soil venting in relation to established soil quality limits is addressed. Finally, we suggest directions for future research and comment on legislative considerations

Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine

Precision medicine is part of the logical evolution of contemporary evidence-based medicine that seeks to reduce errors and optimize outcomes when making medical decisions and health recommendations. Diabetes affects hundreds of millions of people worldwide, many of whom will develop life-threatening complications and die prematurely. Precision medicine can potentially address this enormous problem by accounting for heterogeneity in the etiology, clinical presentation and pathogenesis of common forms of diabetes and risks of complications. This second international consensus report on precision diabetes medicine summarizes the findings from a systematic evidence review across the key pillars of precision medicine (prevention, diagnosis, treatment, prognosis) in four recognized forms of diabetes (monogenic, gestational, type 1, type 2). These reviews address key questions about the translation of precision medicine research into practice. Although not complete, owing to the vast literature on this topic, they revealed opportunities for the immediate or near-term clinical implementation of precision diabetes medicine; furthermore, we expose important gaps in knowledge, focusing on the need to obtain new clinically relevant evidence. Gaps include the need for common standards for clinical readiness, including consideration of cost-effectiveness, health equity, predictive accuracy, liability and accessibility. Key milestones are outlined for the broad clinical implementation of precision diabetes medicine